HLA-A gene knockout using CRISPR/Cas9 system toward overcoming transplantation concerns

Park B, Yoo KH, Kim C (2015) Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. Blood Res Kor Soc Hematol 50:194–203 Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P et al (2011) Donor-specific anti-HLAAbs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 118(22):5957–5964. https://doi.org/10.1182/blood-2011-06-362111 Bray RA, Hurley CK, Kamani NR, Woolfrey A, Müller C, Spellman S et al (2008) National Marrow Donor Program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant 14(9 SUPPL):45–53. https://doi.org/10.1016/j.bbmt.2008.06.014 Figueiredo C, Seltsam A, Blasczyk R (2006) Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. J Mol Med 84(5):425–437. https://doi.org/10.1007/s00109-005-0024-2 Gonzalez S, Castanotto D, Li H, Olivares S, Jensen MC, Forman SJ, Rossi JJ, Cooper LJN (2005) Amplification of RNA-targeting HLA mRNAs. Mol Ther 11(5):811–818. https://doi.org/10.1016/j.ymthe.2004.12.023 Deuse T, Seifert M, Phillips N, Fire A, Tyan D, Kay M, et al (2011) Human leukocyte antigen I knockdown human embryonic stem cells induce host ignorance and achieve prolonged xenogeneic survival. Circulation 124(11 SUPPL. 1) Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJN (2013) Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 122(8):1341–1349. https://doi.org/10.1182/blood-2013-03-478255 Torikai H, Mi T, Gragert L, Maiers M, Najjar A, Ang S et al (2016) Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci Rep 6(1):21757 Available from: http://www.nature.com/articles/srep21757 Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science (80- ) 346(6213):1258096–1258096 [cited 2018 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25430774 Wang H, La Russa M, Qi LS (2016) CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 85(1):227–264 Available from: http://www.annualreviews.org/doi/10.1146/annurev-biochem-060815-014607 Pirouzfar M, Amiri F, Dianatpour M, Takhshid MA (2020) CRISPR/Cas9-mediated knockout of mll5 enhances apoptotic effect of cisplatin in hela cells in vitro. EXCLI J 19:170–182 Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud J-B et al (2016) Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol 17(1):148 [cited 2019 Dec 19]. Available from: http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1012-2 Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 Ebrahimkhani S, Farjadian S, Ebrahimi M (2014) The Royan public umbilical cord blood Bank: does it cover all ethnic groups in Iran based on HLA diversity. Transfus Med Hemother 41(2):134–138 Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SGE (2015) The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 43(D1):D423–D431 [cited 2019 Dec 16]. Available from: http://academic.oup.com/nar/article/43/D1/D423/2438496/The-IPD-and-IMGTHLA-database-allele-variant Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110(13):4576–4583 [cited 2018 Jul 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17785583 Barker JN, Scaradavou A, Stevens CE (2010) Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 115(9):1843–1849. https://doi.org/10.1182/blood-2009-07-231068 Ballen KK, Gluckman E, Broxmeyer HE (2013) Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122:491–498 Rocha V (2016) Umbilical cord blood cells from unrelated donor as an alternative source of hematopoietic stem cells for transplantation in children and adults. Semin Hematol 53(4):237–245. https://doi.org/10.1053/j.seminhematol.2016.08.002 Souillet G, Rey S, Bertrand Y, Pujol M, Pondarré C, Bourgeot JP et al (2000) Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLA-matched and -mismatched situation. Bone Marrow Transplant 26(1):31–43 [cited 2018 Aug 1]. Available from: http://www.nature.com/articles/1702460 Kumar P, Defor TE, Brunstein C, Barker JN, Wagner JE, Weisdorf DJ et al (2008) Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol Blood Marrow Transplant 14(12):1394–1400 [cited 2018 Aug 1]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1083879108004205 Camitta B, Ash R, Menitove J, Murray K, Lawton C, Hunter J et al (1989) Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. Blood 74(5):1852–1857 [cited 2018 Aug 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2529004 Petersdorf EW (2008) Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 20(5):588–593 [cited 2018 Aug 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18674615 Louw VJ, Heyns ADP (2010) The role of the state in establishing a public cord blood stem cell bank. S Afr Med J 100(5):292–294 [cited 2018 Aug 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20460020 Hamidieh AA, Ostadali Dehaghi M, Paragomi P, Navaei S, Jalali A, Ghazizadeh Eslami G et al (2015) Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search. Bone Marrow Transplant 50(4):545–552Available from:. https://doi.org/10.1038/bmt.2014.307 Haga K, Lemp NA, Logg CR, Nagashima J, Faure-Kumar E, Gomez GG, Kruse CA, Mendez R, Stripecke R, Kasahara N, Cicciarelli JC (2006) Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes. Transplant Proc 38(10):3184–3188. https://doi.org/10.1016/j.transproceed.2006.10.158 Figueiredo C, Goudeva L, Horn PA, Eiz-Vesper B, Blasczyk R, Seltsam A (2010) Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion. 50(8):1690–1701. https://doi.org/10.1111/j.1537-2995.2010.02644.x Wiegmann B, Figueiredo C, Gras C, Pflaum M, Schmeckebier S, Korossis S, Haverich A, Blasczyk R (2014) Prevention of rejection of allogeneic endothelial cells in a biohybrid lung by silencing HLA-class I expression. Biomaterials. 35(28):8123–8133. https://doi.org/10.1016/j.biomaterials.2014.06.007 González-Galarza FF, Takeshita LYC, Santos EJM, Kempson F, Maia MHT, da Silva ALS et al (2015) Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 43(D1):D784–D788 [cited 2019 Jan 20]. Available from: http://academic.oup.com/nar/article/43/D1/D784/2438866/Allele-frequency-net-2015-update-new-features-for Colonna M, Borsellino G et al HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1-and NK2-specific natural killer cells. Natl Acad Sci [cited 2018 Aug 4]; Available from: http://www.pnas.org/content/90/24/12000.short Nowak J (2008) Role of HLA in hematopoietic SCT. Bone Marrow Transplant 42(SUPPL. 2):71–76 Petersdorf EW (2013) Genetics of graft-versus-host disease: the major histocompatibility complex. Blood Rev 27(1):1–12 [cited 2018 Jul 25]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0268960X12000720 Crivello P, Ahci M, Maaßen F, Wossidlo N, Arrieta-Bolaños E, Heinold A, Lange V, Falkenburg JHF, Horn PA, Fleischhauer K, Heinrichs S (2019) Multiple knockout of classical HLA class II β-chains by CRISPR/Cas9 genome editing driven by a single guide RNA. J Immunol 202(6):1895–1903. https://doi.org/10.4049/jimmunol.1800257 Mattapally S, Pawlik KM, Fast VG, Zumaquero E, Lund FE, Randall TD et al (2018) Human leukocyte antigen class I and II knockout human induced pluripotent stem cell–derived cells: universal donor for cell therapy. J Am Heart Assoc 7(23):1–13 Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N et al (2019) Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24(4):566–578.e7. https://doi.org/10.1016/j.stem.2019.02.005 Pathak B, Zhao S, Manoharan M, Srivastava V (2019) Dual-targeting by CRISPR/Cas9 leads to efficient point mutagenesis but only rare targeted deletions in the rice genome. 3 Biotech 9(4) Hong C, Sohn H, Lee H, Cho H, Kim T (2017) Antigen presentation by individually transferred HLA class I generated using the multiplex CRISPR-Cas9 system. J Immunother 40(6):201–210. https://doi.org/10.1097/CJI.0000000000000176